# Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors

> **NCT03964727** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 227 (actual)

## Conditions studied

- Metastatic Solid Tumor

## Interventions

- **DRUG:** Sacituzumab Govitecan-hziy

## Key facts

- **NCT ID:** NCT03964727
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-15
- **Primary completion:** 2025-01-15
- **Final completion:** 2026-12
- **Target enrollment:** 227 (ACTUAL)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03964727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03964727, "Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT03964727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*